Paul Bisaro is an accomplished global business leader with more than 25 years of generic and branded pharmaceutical experience, and an exceptional track record of driving company growth through operational execution and corporate transformation. Most recently, from May 2018 until August 2019, Paul served as the Executive Chairman of Amneal Pharmaceuticals, Inc. Prior to that appointment, May 2017 to May 2018, Mr. Bisaro was President and Chief Executive Officer, as well as, a member of the Impax Laboratories Board of Directors.
In May 2018, Impax merged with Amneal Pharmaceuticals and Mr. Bisaro assumed the role of Executive Chairman of the merged company. Prior to joining Impax, Mr. Bisaro served as Executive Chairman of Allergan, plc from July 2014 to November 2016, as President and CEO of Actavis, plc (and its predecessor firm Watson Pharmaceuticals Inc.) from September 2007 to July 2014. Mr. Bisaro served on the Board of Allergan plc. (and its predecessor firms) from September 2007 until August 2018.
Previously, he also served as President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (Barr), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999, served in various additional executive leadership capacities. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds, from 1989 to 1992. He also served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C.
What is Paul Bisaro's net worth?
The estimated net worth of Paul Bisaro is at least $277,578.24 as of August 16th, 2021. Mr. Bisaro owns 196,864 shares of TherapeuticsMD stock worth more than $277,578 as of November 15th. This net worth estimate does not reflect any other assets that Mr. Bisaro may own. Learn More about Paul Bisaro's net worth.
How do I contact Paul Bisaro?
Has Paul Bisaro been buying or selling shares of TherapeuticsMD?
Paul Bisaro has not been actively trading shares of TherapeuticsMD during the last quarter. Most recently, on Monday, August 16th, Paul Bisaro bought 50,000 shares of TherapeuticsMD stock. The stock was acquired at an average cost of $0.79 per share, with a total value of $39,500.00. Following the completion of the transaction, the director now directly owns 196,864 shares of the company's stock, valued at $155,522.56. Learn More on Paul Bisaro's trading history.
Who are TherapeuticsMD's active insiders?
Are insiders buying or selling shares of TherapeuticsMD?
In the last twelve months, TherapeuticsMD insiders bought shares 1 times. They purchased a total of 1,200 shares worth more than $2,040.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 14,500 shares worth more than $33,495.00. The most recent insider tranaction occured on August, 21st when Director Cooper C Collins bought 1,200 shares worth more than $2,040.00. Insiders at TherapeuticsMD own 2.3% of the company.
Learn More about insider trades at TherapeuticsMD. Information on this page was last updated on 8/21/2024.
